top of page
Brain Scans

Join VerAvanti's Early Access Program
Shape the Future of Intravascular Imaging

Be among the first to evaluate or represent VerAvanti’s pioneering SFE (Scanning Fiber Endoscope) technology. Designed to deliver real-time, forward-looking, full-color imaging, SFE sets a new standard in intravascular visualization.

Interventional Cardiologists & Vascular Surgeons

Join to evaluate VerAvanti’s SFE in complex CTO interventions and stroke procedures.


Pain Points:

  • Poor visualization in tortuous or occluded anatomy

  • Cumulative radiation exposure during complex procedures

  • Need for fast, real-time diagnostic feedback at the point of care


How We Plan to Help:

  • We will deliver high-resolution, forward-looking imaging to enhance procedural precision.

  • Our radiation-free, single-use design will reduce infection risk and turnaround time.

  • We aim to improve efficiency and confidence in treating complex lesions.

Hospitals & Academic Centers

Collaborate with us to gain early clinical experience and participate in research studies with VerAvanti’s advanced imaging technology.


Pain Points:

  • Delayed access to new devices limits clinical competitiveness

  • Limited physician access and device availability reduce procedural efficiency and revenue growth from breakthrough technologies

  • Pressure to publish and lead in innovation-driven specialties


How We Plan to Help:

  • Pursue FDA Medical Device Breakthrough Designation to enable earlier clinical access to our innovative technology

  • Streamline workflow and reduce overhead in high-demand intravascular procedures

  • Support reimbursement readiness through structured clinical use

  • Foster research collaborations with data access and co-authorship opportunities

Distributors & Strategic Partners

Engage with VerAvanti ahead of commercial launch to position yourself at the forefront of imaging innovation.


Pain Points:

  • Limited differentiation in competitive medtech markets

  • Demand for clinically validated, regulatory-ready products

  • Need for strong technical and marketing support from suppliers


How We Plan to Help:

  • Offer pre-market access to an imaging device with disruptive clinical potential

  • Empower you with robust clinical evidence, training programs, and market strategy support

  • Build trusted, long-term partnerships driven by global compliance and patient outcomes

Who Should Join?

VerAvanti’s Early Access program is designed for forward-thinking professionals and organizations eager to be at the forefront of intravascular innovation. Whether you're a clinician, hospital leader, or commercial partner, this is your opportunity to engage with breakthrough technology before full market release.

VerAvanti_Mid Right(Background) copy.jpg

Academic Research Participation

Select institutions will contribute to structured, investigator-led studies exploring clinical applications of the SFE Partners will:

  • Help generate early clinical evidence

  • Co-author abstracts and publications

  • Early access to our FDA Breakthrough Device (pending clearance) to stay ahead of the competition

Early Device Access

Several SFE units will be distributed to academic centers for real-world evaluation. You will have the opportunity to:

  • Perform hands-on testing in clinical workflows

  • Share usability and performance feedback

  • Collect data using an exclusive pre-FDA device, helping you stay ahead and lay the foundation for long-term clinical and academic influence

Direct Access to Dr. Luis Savastano

Participate in exclusive monthly strategy sessions with our Chief Medical Officer, Dr. Luis Savastano. These virtual meeting will offer a forum for:

  • Real-time study updates and clinical insights

  • Case reviews and image analysis

  • Peer exchange with fellow academic collaborators

What Can You Expect?

By joining VerAvanti’s Early Access program, you will gain more than just early exposure; you will become part of a structured, research-driven initiative that helps shape the future of intravascular imaging.

Here is what participation looks like:

Register Your Interest in VerAvanti’s Early Access Program

Interested in early access? Let us know how you'd like to get involved.

Region
What type of early access are you interested in?
LongGradient.webp

Procedural Efficiency & Capacity

Our technology will deliver high-resolution, live imaging designed to accelerate workflows and enhance procedural throughput. This will improve accuracy and reduce time spent on each case, leading to better patient outcomes.

LongGradient.webp

Fiber Optic Technology

Utilizing advanced fiber optics, our system will provide vivid, high-resolution live images with exceptional clarity and color fidelity. This precision will support detailed visualization of complex anatomy.

LongGradient.webp

Minimal Invasiveness

Our technology will support minimally invasive procedures by providing real-time, high-resolution imaging that guides clinicians with precision, minimizing tissue trauma and enhancing recovery.

LongGradient.webp

Radiation Free, Single-Use Design

Our device will offer radiation-free imaging through a disposable, single-use design that eliminates contamination risks and the need for sterilization, improving safety and operational efficiency.

LongGradient.webp

Diagnostic Accuracy

We will deliver clear, high-resolution visuals that enable clinicians to make accurate, real-time diagnoses, reducing the need for repeat interventions and enabling targeted treatments.

LongGradient.webp

Real-Time Visual Feedback

Our system will provide immediate, live imaging feedback during procedures, empowering clinicians to adjust techniques dynamically and improve procedural success rates.

Why Join Our Early Access Program?

VerAvanti will transform how clinicians visualize and treat chronic total occlusions (CTOs), strokes, and other intravascular diseases. Although our products are not yet commercially available, we are actively advancing through the U.S. FDA review process, with clearance expected in the first half of 2026. We will then pursue CE marking for the EU and UK shortly thereafter. For markets outside North America and Europe, we plan to begin pursuing local regulatory approvals in early 2027.


Our patented SFE technology will deliver:

Meet our Key Leader

savastano-luis-1790040632_edited.png

Dr. Luis Savastano
Chief Medical Officer, VerAvanti | Neurosurgeon & Imaging Innovator

Dr. Luis Savastano is a surgeon-scientist, inventor, and serial founder dedicated to solving unmet clinical needs through translational research and the development of breakthrough medical technologies. A hybrid cerebrovascular neurosurgeon, he specializes in both microsurgical and endovascular treatment of ischemic and hemorrhagic stroke.

​

He currently serves at the University of California, San Francisco (UCSF) as Co-Chief of NeuroEndovascular Surgery, Medical Director of Cerebrovascular Neurosurgery, Program Director of the CAST-approved Cerebrovascular Fellowship, and Principal Investigator of the Translational Neurosurgery and Technology Lab (TNTLab). In these roles, Dr. Savastano leads a multidisciplinary team working at the intersection of clinical care, innovation, and device development.

​

As Chief Medical Officer at VerAvanti, Dr. Savastano plays a key role in shaping the company’s clinical research and validation strategy. He leads efforts to advance the SFE angioscopy platform through investigator-led studies and strategic collaborations with early access partners. Through regular research meetings and case-based discussions, he works closely with academic institutions and practicing clinicians to refine the technology and accelerate its path to clinical adoption.

​

Dr. Savastano has conducted pioneering research on VerAvanti’s SFE platform and was among the earliest to explore its use in the evaluation of carotid artery disease and stroke, demonstrating its potential to provide real-time, high-resolution intravascular visualization. His work underscores a strong commitment to translating innovation into meaningful clinical tools that improve outcomes and reshape standards of care.

  • How does the VerAvanti SFE compare to current technologies like OCT and IVUS?
    The SFE provides forward-looking, true-color, real-time imaging. OCT and IVUS capture grayscale side-view frames that require interpretation. SFE makes visualization intuitive by showing what’s directly ahead, helping identify plaque rupture, calcified nodules, and true lumen pathways more easily and accurately.
  • Can the SFE see through blood inside live vessels?
    The commercial version requires saline flushing for clear images. A next-gen model using infrared wavelengths to see through blood is under development. It's a top R&D priority and expected to be a major leap forward once commercialized.
  • What specialties beyond cardiology are being explored?
    SFE is currently being tested across neurovascular, gastroenterology, ENT, pulmonology, urology, dental, and fluorescence-guided imaging. The initial commercial focus is intravascular, but the tech is being validated for full-body applications from head to toe.
  • Isn’t angioscopy an old technology? What makes this different?
    Yes, angioscopy existed in the 1990s but failed due to poor resolution, patient discomfort, and bulky probes. VerAvanti’s version solves these issues with sub-1mm fiber optics, MEMS-driven spiral scanning, no radiation, and clear imaging that works in real time.
  • Why is forward-looking imaging such a big deal for interventionists?
    It eliminates the need to mentally reconstruct anatomy from side-views and shadows. Instead of interpreting indirect signals, clinicians can directly see what lies ahead. This improves precision, reduces the risk of procedural errors, and speeds up decision-making.
  • Can the SFE see through blood inside live vessels?
    The commercial version requires saline flushing for clear images. A next-gen model using infrared wavelengths to see through blood is under development. It's a top R&D priority and expected to be a major leap forward once commercialized.
  • Can the SFE assist with stent planning or post-placement evaluation?
    Yes. The SFE enables clinicians to plan stent deployment, confirm positioning, and evaluate healing over time. It shifts imaging from static to dynamic, helping catch issues that might be missed using legacy systems.
  • How is VerAvanti handling the challenge of flushing and oxygenation during live procedures?
    Current saline flushing may limit use in some cases due to temporary blood displacement. However, ongoing R&D into an infrared-capable SFE aims to eliminate this need altogether, allowing visualization through blood without impacting downstream oxygenation.
  • What kind of data and software support does the SFE provide?
    While detailed analysis remains under wraps, the company is building software capabilities at the console level to interpret imaging, categorize findings, and potentially integrate with AI in future iterations to assist with diagnosis and navigation.
  • When will this be available for broader clinical use?
    The company is moving toward FDA clearance and has already invested over $40M in R&D, protected by 50+ patents. The intravascular market is the first beachhead, with expansion planned as regulatory milestones are met and manufacturing scales.

frequently asked questions

We have put together answers to the most common questions about VerAvanti’s Early Access program. This section will help you understand how the program works and the benefits you will receive by joining. If you don’t see your question here, please feel free to reach out to our team directly.

bottom of page